California Public Employees Retirement System Continues to Hold Stake in TG Therapeutics, Inc. (TGTX)

California Public Employees Retirement System continued to hold its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 106,400 shares of the biopharmaceutical company’s stock at the end of the second quarter. California Public Employees Retirement System owned approximately 0.17% of TG Therapeutics worth $1,069,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legal & General Group Plc increased its holdings in shares of TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 384 shares during the period. Bank of America Corp DE increased its holdings in shares of TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,395 shares during the period. American International Group Inc. increased its holdings in shares of TG Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 22,681 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 1,500 shares during the period. UBS Group AG increased its holdings in shares of TG Therapeutics by 34.4% in the first quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 3,736 shares during the period. Finally, Teachers Advisors LLC increased its holdings in shares of TG Therapeutics by 7.1% in the first quarter. Teachers Advisors LLC now owns 75,432 shares of the biopharmaceutical company’s stock valued at $879,000 after purchasing an additional 5,000 shares during the period. 49.94% of the stock is currently owned by institutional investors.

Shares of TG Therapeutics, Inc. (TGTX) opened at $8.45 on Friday. TG Therapeutics, Inc. has a 12 month low of $4.10 and a 12 month high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 155.38%. equities research analysts expect that TG Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “California Public Employees Retirement System Continues to Hold Stake in TG Therapeutics, Inc. (TGTX)” was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/12/california-public-employees-retirement-system-continues-to-hold-stake-in-tg-therapeutics-inc-tgtx.html.

TGTX has been the topic of a number of recent research reports. BidaskClub raised TG Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 16th. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 16th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a report on Tuesday, October 3rd. Finally, Zacks Investment Research downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $25.11.

TG Therapeutics Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply